SFX by Ex Libris Inc.

Title:	Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
Source:	Science [0036-8075] Changelian, P S yr:2003

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Walunas, T L L. "CTLA-4 can function as a negative regulator of T cell activation." Immunity 1.5 (1994): 405-413.
description	2.	Chan, Tsun Leung L. "Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer." Nature genetics 38.10 (2006): 1178-83.
description	3.	O'Shea, John J J. "New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway." Current opinion in rheumatology 17.3: 305-311.
description	4.	Evans, W E E. "Pharmacogenomics: translating functional genomics into rational therapeutics." Science 286.5439 (1999): 487-91.
description	5.	Borie, Dominic C. "Combined Use of the JAK3 Inhibitor CP-690,550 with Mycophenolate Mofetil to Prevent Kidney Allograft Rejection in Nonhuman Primates." Transplantation 80.12 (2005): 1756-64.
description	6.	Evans, William E E. "Pharmacogenomics--drug disposition, drug targets, and side effects." The New England journal of medicine 348.6 (2003): 538-49.
description	7.	Leach, D R R. "Enhancement of antitumor immunity by CTLA-4 blockade." Science 271.5256: 1734-1736.
description	8.	Krummel, J P F. "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation." The Journal of experimental medicine 182.2 (1995): 459-65.
description	9.	Evans, WE. "Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects." The New England journal of medicine 348.6 (2003): 538-549.
description	10.	Roses, ALLEN D. "Pharmacogenetics and the practice of medicine." Nature 405.6788 (2000): 857-865.
description	11.	Eichelbaum, M. "Pharmacogenomics and individualized drug therapy." Annual Review of Medicine 57.1 (2006): 119-137.
description	12.	Durbin, Richard M. "A map of human genome variation from population-scale sequencing." Nature 467.7319 (2010): 1061-1073.
description	13.	Lorenzetti, D. "A 1.5-Mb deletion in 17p11.2-p12 is frequently observed in Italian families with hereditary neuropathy with liability to pressure palsies." American journal of human genetics 56.1 (1995): 91-8.
description	14.	Grewal, I S S. "Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis." Science 273.5283 (1996): 1864-7.
description	15.	Lindsten, T. "Characterization of CTLA-4 structure and expression on human T cells." The journal of immunology 151.7 (1993): 3489-3499.
description	16.	Martin, Robyn L I. "Germline epimutation of MLH1 in individuals with multiple cancers." Nature genetics 36.5 (2004): 497-501.
description	17.	Nebert, Daniel W W. "Clinical importance of the cytochromes P450." Lancet, The 360.9340 (2002): 1155-1162.
description	18.	Hawiger, D. "Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo." The Journal of experimental medicine 194.6 (2001): 769-79.
description	19.	Legendre, C. "JAK3 inhibition: what potential for the future?" Transplantation Research 2.Suppl 1 (2013).
description	20.	Quaedackers, Monique E. "Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients." Transplantation 88.8 (2009): 1002-9.